Restoring brain
function through
biophysics.
Fareon is pioneering a new class of biophysics therapy designed to support repair and recovery without drugs or systemic side effects.
Our first-in-class feasibility study was randomized, triple-blind and sham-controlled. We found that Microtesla Magnetic Therapy (MMT) improved cognition and mood in Long COVID brain fog. No device- or therapy-related adverse events were reported. See the clinical data →
“This is the first data I have seen suggesting that restoration of lost function may be possible.”
Director of Rehabilitation Innovation, Mount Sinai
The Fareon Restore™ platform targets biology shared across many brain disorders.
These conditions are often characterized by unresolved inflammation, oxidative stress, mitochondrial dysfunction, and impaired cellular repair. Current treatments such as drugs, implants, and electrical stimulation, can affect the whole body with off-target effects, require surgery, or have limited reach in the brain. Biophysics offers a better solution.
We are starting with cognitive impairment from Long COVID, a large, untreated population without evidence-based therapies. Data from studies in our first indication will guide platform expansion into other conditions with similar biology.
Fareon Restore is a flexible, reusable platform for biophysics therapy
Fareon is building a therapeutic platform, not a single product. Fareon Restore is designed to be delivered as a physician-prescribed service, shipped to patients for at-home delivery of MMT under clinical oversight. Durable hardware supports multiple treatment cycles, and adaptable indication-specific waveforms.
Long COVID isn't going away.
Cognitive impairment is a major part of the burden.
The pandemic may be behind us, yet Long COVID continues to affect millions of Americans, with no approved treatment for the condition. Brain fog is among its most common and disabling symptoms linked to reduced ability to work.
Over 4.4 years, 27% of Long COVID patients went on to develop MCI, versus 1% of COVID-negative controls.9 Treating Long COVID now is the most direct way to blunt that second-order risk.
of developing MCI
- 1. KFF analysis of CDC Household Pulse Survey (2024).
- 2. Elboraay et al., BMC Neurology (2025).
- 3. Jia et al., Front Public Health (2026).
- 4. Tian et al., JAMA Netw Open (2026).
- 5. Shah et al., JAMA Netw Open (2026).
- 6. Hampshire et al., NEJM (2024).
- 7. Kim, Communications Medicine (2025).
- 8. Living with Long COVID (CDC, 2024).
- 9. Frontera et al., Alzheimer's & Dement. (2026).
First-in-human trial completed
Findings of feasibility study to be confirmed in larger controlled trials.
Let's work together to reduce human suffering
We're partnering with investors, clinicians, and institutions to bring Fareon Restore to deliver Microtesla Magnetic Therapy to the patients who need better options. Interested in working with us? We'd love to talk.